Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo
Authors:
- 26 September 2016
- journal article
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 17 (3) , 281-291
Abstract
Anaplastic thyroid cancer (ATC) is a locally aggressive type of thyroid tumor with high rate of distant metastases. It is often incurable because it does not respond to radioiodine, radiotherapy, or chemotherapy. With conventional treatment, the mediKeywords
This publication has 34 references indexed in Scilit:
- Novel Approaches in Anaplastic Thyroid Cancer TherapyThe Oncologist, 2014
- Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancerOncotarget, 2014
- Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid CancerThe Oncologist, 2011
- Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid MicrocarcinomaAnnals of Surgical Oncology, 2008
- Where Do We Stand with Targeted Therapy of Refractory Thyroid Cancer?—Utility of RECIST CriteriaThyroid®, 2008
- Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment ApproachesAnnals of Surgical Oncology, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean PopulationYonsei Medical Journal, 2004
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003